San Francisco startup Construction Therapeutics can be working on an oral, once-everyday GLP-1 drug known as GSBR-1290—the drug surpassed Wall Street’s expectations in June any time a mid-phase study showed regular weight loss of all over six% and it ideas to get started on A further mid-phase trial in direction of the end of the calendar year�